Transfer RNAs (tRNAs) have a crucial role in protein synthesis, and in recent years, their therapeutic potential for the treatment of genetic diseases — primarily those associated with a mutation altering mRNA
tRNA therapeutics for genetic diseases. Nat Rev Drug Discov (2023). 通讯作者: Jeff CollerJohns Hopkins University School of Medicine BiochemistryRNA 生物学和治疗学杰出教授 在信使 RNA 稳定性和翻译领域取得了开创性的发现。从核糖体到患者,他正在推动这一令人兴奋的领域的发展,旨在开发新的疗法来治疗毁灭性...
参考资料 1.tRNA therapeutics for genetic diseases. 2.Emerging roles of tRNA in adaptive translation, signalling dynamics and disease. 3.The expanding world of tRNA modifications and their disease relevance. FYI:总结生物医药更多知识点,敬请关注公众平台「佰傲谷BioValley」 部分图源网络,侵权联删 ...
2024, Nucleic Acid Therapeutics tRNA therapeutics for genetic diseases 2024, Nature Reviews Drug Discovery View all citing articles on Scopus © 2023 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology. ...
在此之前,成立于2015年的ReCode Therapeutics已经在探索将tRNA用于治疗囊性纤维化。 参考资料: https://www.fiercebiotech.com/biotech/flagship-unveils-its-next-rna-bet-50m-for-alltrna-to-explore-thousands-genetic-diseases 开放转载 欢迎...
The world’s first tRNA platform company, deciphering tRNA biology and pioneering tRNA therapeutics to treat thousands of diseases.
tRNAs are key adaptor molecules that decipher the genetic code during translation of mRNAs in protein synthesis. In contrast to the traditional view of tRNAs as ubiquitously expressed housekeeping molecules, awareness is now growing that tRNA-encoding ge
Some inhibitors targeting DNA methylation, such as zebularine, oligodeoxynucleotides, azacytidine, and decitabine, have been developed for epigenetics-driven therapeutics (Zhou et al.2002; Schaefer et al.2010). Azacytidine has been shown to inhibit DNMT2-driven methylation of cytosine 38 in tRNAAsp,...
Following a brief introduction to the aminoacylation reaction, we will discuss efforts to target prokaryotic organisms, move on to eukaryotic pathogens, and then conclude with prospects for therapeutics against noninfectious diseases, including cancer and neurological diseases. Aminoacylation reaction and ...
Board Director of Alltrna. "The team has made significant advancements to confirm that Alltrna's platform can turn tRNA's sophisticated biology into programmable medicines to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation....